# RegenBrief

> Clinical archive and research notes on functional longevity, frailty, cognition, and regenerative medicine — curated in Korean. Provided by DYPHI Functional Longevity Center (DYPHI Inc.).

This site indexes global clinical trials in stem cells, exosomes, and functional aging, curated in Korean for clinicians and researchers. Trial statuses are auto-synced daily with ClinicalTrials.gov API v2.

## What this site offers

- **Clinical trial summaries** in Korean: trial design, clinical significance, limitations, and Korean regulatory context
- **Research notes**: frailty, sarcopenia, cognitive decline, functional assessment
- **Policy analysis**: Korean MFDS, HIRA, and MoHW regulatory trends for advanced biopharmaceuticals and regenerative medicine
- **Cross-referencing**: filter by indication, cell source, trial phase, or sponsor region

## Site sections

### Getting Started / Overview (~500 tokens)
- **Home**: https://flc.dyphi.com/
  Overview of all three content types with recent entries. Includes aggregate counts for clinical archive, research notes, policy analyses, and indication coverage.

- **About**: https://flc.dyphi.com/about/
  Mission, content structure, editorial principles, and operator context. Explains the human/machine division of labor (metadata auto-synced; interpretation written by humans). (~800 tokens)

### Clinical Archive (~600–1,500 tokens per entry)
All entries follow a consistent structure: trial metadata table, clinical design, clinical significance, limitations, related trials.

- **Index**: https://flc.dyphi.com/clinical-archive/
  Full list of curated clinical trials, sortable by indication / cell source / phase / region.

- **WJ-MSC Chronic Spinal Cord Injury — Phase I**: https://flc.dyphi.com/clinical-archive/2025-wj-msc-spinal-cord-injury/
  NCT05152290 · Intrathecal WJ-MSC · Safety + ASIA scale · 10 patients (~900 tokens)

- **Laromestrocel Alzheimer's Disease — Phase 2a**: https://flc.dyphi.com/clinical-archive/2025-laromestrocel-ad-phase2a/
  NCT05233774 · IV BM-MSC (Longeveron) · ARIA-free, cognitive signal · 49 patients (~1,100 tokens)

- **WJ-MSC Knee Osteoarthritis — Warsaw**: https://flc.dyphi.com/clinical-archive/2024-wj-msc-knee-osteoarthritis-warsaw/
  Intra-articular WJ-MSC · Cartilage regeneration (~900 tokens)

- **AD-MSC Exosome Alzheimer's Disease — Intranasal**: https://flc.dyphi.com/clinical-archive/2023-ahamscs-exos-ad-intranasal/
  Intranasal exosome delivery for AD · Cell-free approach (~1,000 tokens)

- **ExoFlo ARDS — Phase 2/3**: https://flc.dyphi.com/clinical-archive/2025-exoflo-ards-phase23/
  IV MSC-derived exosomes for COVID-19 ARDS (~900 tokens)

Browse-by filters:
- By indication: https://flc.dyphi.com/by-indication/
- By cell source: https://flc.dyphi.com/by-cell-source/
- By phase: https://flc.dyphi.com/by-phase/
- By region: https://flc.dyphi.com/by-region/

### RegenBrief (~800–2,000 tokens per entry)
- **Index**: https://flc.dyphi.com/regenbrief/
  Indication-by-indication guides on conditions treatable via stem cells and exosomes. Covers pathophysiology, mechanism of cell therapy, current evidence level, and treatment feasibility.

### Policy Analysis (~800–2,000 tokens per entry)
- **Index**: https://flc.dyphi.com/policy/
  Korean regulatory landscape: MFDS advanced biopharmaceuticals, HIRA reimbursement, regenerative medicine act updates.

## Key data schema (Clinical Archive entries)

Each entry carries structured front matter:
- `nct_id`: ClinicalTrials.gov ID
- `sponsor` / `sponsor_country`
- `cell_source`: one of wj-msc, uc-msc, bm-msc, ad-msc, msc-exosome, ipsc, nsc, hsc, etc.
- `cell_origin`: allogeneic | autologous
- `indication`: mapped to controlled vocabulary (alzheimers-disease, spinal-cord-injury, knee-osteoarthritis, etc.)
- `phase`: phase-1 | phase-2 | phase-2a | phase-2b | phase-3
- `status`: recruiting | active | completed | terminated
- `delivery_route`: IV | intrathecal | intra-articular | intranasal | etc.
- `patient_count`
- `publication` + `publication_doi`

## Machine-readable resources

- **AI capability declaration**: https://flc.dyphi.com/skill.md
- **Access rules**: https://flc.dyphi.com/agent-permissions.json
- **Sitemap**: https://flc.dyphi.com/sitemap.xml
- **RSS feed**: https://flc.dyphi.com/feed.xml
- **Clean markdown index**: https://flc.dyphi.com/for-ai/

## Operator

RegenBrief is provided by DYPHI Functional Longevity Center, operated by DYPHI Inc. — developers of AndanteFit, a LiDAR-based physical function assessment system.
Site content is for academic reference only. Not medical advice.